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Abstract
Background: Mitochondrial diseases comprise a diverse set of clinical disorders that affect multiple organ systems
with varying severity and age of onset. Due to their clinical and genetic heterogeneity, these diseases are difficult
to diagnose. We have developed a targeted exome sequencing approach to improve our ability to properly
diagnose mitochondrial diseases and apply it here to an individual patient. Our method targets mitochondrial DNA
(mtDNA) and the exons of 1,600 nuclear genes involved in mitochondrial biology or Mendelian disorders with
multi-system phenotypes, thereby allowing for simultaneous evaluation of multiple disease loci.
Case Presentation: Targeted exome sequencing was performed on a patient initially suspected to have a
mitochondrial disorder. The patient presented with diabetes mellitus, diffuse brain atrophy, autonomic neuropathy,
optic nerve atrophy, and a severe amnestic syndrome. Further work-up revealed multiple heteroplasmic mtDNA
deletions as well as profound thiamine deficiency without a clear nutritional cause. Targeted exome sequencing
revealed a homozygous c.1672C > T (p.R558C) missense mutation in exon 8 of WFS1 that has previously been
reported in a patient with Wolfram syndrome.
Conclusion: This case demonstrates how clinical application of next-generation sequencing technology can
enhance the diagnosis of patients suspected to have rare genetic disorders. Furthermore, the finding of
unexplained thiamine deficiency in a patient with Wolfram syndrome suggests a potential link between WFS1
biology and thiamine metabolism that has implications for the clinical management of Wolfram syndrome patients.
Background
Mitochondrial diseases are a clinically heterogeneous set
of disorders that are caused by defects in mitochondria,
the organelles responsible for producing most of the cel-
lular ATP in humans [1]. Multiple organ-systems are
typically affected in these disorders, with neurologic and
myopathic features being the most prominent [2]. Com-
mon clinical features of mitochondrial disease include
skeletal myopathy accompanied by exercise intolerance,
cardiomyopathy, sensorimotor peripheral polyneuropa-
thy, sensorineural deafness, optic atrophy, diabetes mel-
litus, seizures, and ataxia [3]. These disorders can be
caused by mutations in the nuclear or mitochondrial
genomes, and over 100 loci have been identified to date
[4].
The clinical and genetic heterogeneity of mitochondrial
diseases as well as the technical difficulty of assessing
mitochondrial function create a significant diagnostic
challenge [5]. One major source of cost and time delays
in the clinical evaluation of patients with suspected mito-
chondrial disease is the use of sequential genetic tests to
evaluate individual disorders; as such, a systematic
genetic test could accelerate the diagnostic process and
reduce overall cost. In the present report, we describe a
suspected case of mitochondrial disease whose diagnosis
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targeted exome sequencing.
Case Presentation
In January 2008, a 61-year-old man with a history notable
for diabetes mellitus (DM), autonomic neuropathy, dif-
fuse brain atrophy, optic nerve atrophy (OA), and pro-
found amnesia was referred to us to establish neurologic
care. The patient carried a diagnosis of multiple system
atrophy- cerebellar type (MSAc), principally because of
severe cerebellar and brainstem atrophy on MRI.
The patient’s early history was remarkable only for
childhood bedwetting and urinary urgency as a young
adult. He was otherwise well during this time and was a
talented athlete who completed college and practiced as
an accountant. In his early 20s, he developed bladder
dysfunction of unclear etiology requiring intermittent
straight catheterization, as well as erectile dysfunction.
At age 33, he was diagnosed with DM, presumed to be
type 1, and began treatment with insulin therapy.
Although there is no biochemical data available from the
time of his original diagnosis, recent testing demon-
strated a random C-peptide level of 0.6 ng/mL (reference
range 0.9 to 4.3 ng/mL) at a time when his blood glucose
was 83 mg/dL. He takes an average of 24 units of insulin
per day, and has had good glycemic control with hemo-
globin A1c measurements ranging between 6.5 and 7.2%
over the last several years. He has had no evidence of
retinopathy, or other microvascular or macrovascular
complications. He had polyuria and polydipsia at the
time of his initial DM diagnosis, but these symptoms
resolved once he initiated insulin therapy.
The patient began dressing in strange colors in his 30s,
and color blindness was ultimately diagnosed in his 40s.
At age 53, the patient presented for a routine screening
ophthalmology exam and was discovered to have bilateral
OA with preserved vision. Brain MRI at that time revealed
severe atrophy of the cerebellar hemispheres and vermis,
pons, and middle cerebellar peduncles as well as moderate
cerebral atrophy; a more recent study at age 61 showed
these findings as well as more severe cerebral atrophy
(Figure 1). Despite these radiographic findings, the patient
and his wife reported no gait instability or upper extremity
incoordination.
During his late 50s, the patient’s neurologic status dete-
riorated. Formal neuropsychological evaluation revealed
profound anterograde amnesia, with additional impair-
ments in cognitive flexibility, executive function, naming,
and high order visual processing skills. Attention span,
mental tracking, verbal abstract reasoning, complex audi-
tory instructions, and visual spatial functions were pre-
served. From a psychiatric perspective, he developed
symptoms of depression, which responded to treatment
with sertraline.
In parallel with the decline in his memory, the patient
also developed progressive autonomic neuropathy, with
gastroparesis and severe postural hypotension. The auto-
nomic dysfunction exceeded what might be expected from
his diabetes mellitus, given his good glycemic control and
the absence of other diabetic complications. His bladder
dysfunction worsened and he required suprapubic catheter
placement at the age of 61. Due to his multiple functional
deficits, the patient became unable to work and is now
completely reliant upon his wife for care.
Regarding his family history, the patient was born to
Ashkenazi Jewish parents and there was no parental con-
sanguinity. His mother died from melanoma, and his
father died from multiple strokes and a myocardial
infarction. He has two adult daughters, one of whom has
attention deficit hyperactivity disorder (ADHD) and
Tourette syndrome, while the other suffers from chronic
urinary tract infections. His maternal grandmother had
type 2 DM, and a maternal first cousin had type 1 DM.
No other close relatives have suffered from endocrine,
psychiatric, or neurologic disease.
On physical examination, he appeared generally medi-
cally well. He weighed 79 kilograms and was 178 cm tall,
yielding a body mass index of 25. Postural hypotension
was evident with systolic blood pressure falling from 150
to 95 after one minute of standing, though asymptomatic.
Funduscopic examination revealed optic atrophy bilater-
ally with no sign of diabetic retinopathy. Visual acuity was
20/40 in each eye. Pupil responses to light and accommo-
dation were normal. Eye movements were normal with
the exception of saccadic intrusion into horizontal smooth
pursuit. Clinical examination revealed high tone hearing
loss bilaterally. Audiometry demonstrated moderate sen-
sorineural hearing loss in the high frequencies on the left,
and mild sensorineural hearing loss in the mid-frequencies
on the right sloping to a severe loss in the high frequencies
(Figure 2). Word recognition was excellent in both ears;
98% on the right and 96% on the left. Muscle tone in the
extremities was normal, bulk was intact, and strength was
full. There was no evidence of dysmetria with finger-to-
nose and heel-to-shin testing, and gait was slow but stable.
His affect was flat and he was passive throughout the
interview, speaking only when spoken to. He was not
oriented to time or place. He could repeat four words, but
could not learn them despite multiple attempts. He was
unable to provide information concerning major current
political or national news. He could, however, recall sizable
fragments of remote memory from his college years.
The absence of the cerebellar motor syndrome and the
presence of a profound amnestic syndrome on examina-
tion called the patient’s diagnosis of MSAc into question
[6], and we undertook re-evaluation of his case to explore
alternate diagnoses. His laboratory work-up revealed an
undetectable thiamine level, a surprising finding given his
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ascribed his amnestic disorder to presumed long-stand-
ing thiamine deficiency, but repletion produced minimal
clinical impact. The involvement of multiple systems
suggested the possibility of a mitochondrial disorder.
Genetic testing for OPA1, MELAS, MERFF, LHON and
NARP were negative, however analysis of mitochondrial
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Figure 1 MRI at age 61 demonstrating severe atrophy of the cerebral hemispheres, cerebellum, and brainstem. A-F: 3-D SPGR coronal
MRI; G, H: T1 sagittal MRI; I-L: FLAIR axial MRI, showing white matter signal hyperintensities.
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Page 3 of 7Figure 2 Results of audiometric testing at age 61 conforming to ANSI 1969 standards. ANSI = American National Standards Institute; dB =
decibel; Hz = hertz; PTA = pure tone average.
Figure 3 Results of MitoExome sequencing. Rare, protein-modifying variants were prioritized, revealing a homozygous c.1672C > T (p.R558C)
missense mutation in exon 8 of WFS1 that has previously been reported in a patient with Wolfram syndrome [9].
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heteroplasmic deletions. Biochemical testing revealed a
minor defect in complex I of the electron transport
chain. COX and SDH staining of the muscle biopsy spe-
cimen were unremarkable, and the mitochondria
appeared grossly normal on electron microscopic exami-
nation. Occasional central vacuoles and tubular aggre-
gates were seen in the myocytes, which were felt to be
consistent with a mild non-specific myopathy.
Given the diagnostic uncertainty and concern for a
mitochondrial disorder, the patient was enrolled in the
mitochondrial disease registry at Massachusetts General
Hospital. As part of this program, a sample of the
patient’s DNA from whole blood underwent targeted
exome ("MitoExome”) sequencing. Mitochondrial DNA
and the exons of 1,600 nuclear genes either encoding
mitochondrial proteins or implicated in Mendelian disor-
ders with multi-system phenotypes were targeted using
hybrid selection [7]. Amplified targets were sequenced on
the Illumina GAIIx platform. Rare, protein-modifying
variants found to be homozygous or potentially com-
pound heterozygous were prioritized (Figure 3), revealing
an X-linked functional polymorphism c.937G > T (p.
D313Y) in GLA that is not considered pathogenic [8] and
a homozygous c.1672C > T (p.R558C) missense mutation
in exon 8 of WFS1 that has previously been reported in a
patient with Wolfram syndrome [9]. No heteroplasmic
mtDNA deletions were detected in whole blood. The
patient’s WFS1 mutation was verified through Sanger
sequencing in a CLIA-certified laboratory, though not
without complications; the initial report came back nega-
tive and only after requested follow-up was the homozy-
gous mutation detected, thereby confirming the diagnosis
of Wolfram syndrome.
Discussion and Conclusions
Wolfram syndrome (OMIM #222300) is an autosomal
recessive disorder also known as DIDMOAD for its
typical clinical features of Diabetes Insipidus, Diabetes
Mellitus, Optic Atrophy and Deafness [10]. The mini-
mum criteria for the diagnosis of Wolfram syndrome
are the presence of diabetes mellitus and optic atrophy,
both of which usually occur by the age of fifteen [11].
The disorder is also associated with diverse neurologic
and psychiatric symptoms, including cognitive impair-
ment [12]. Though with genetic data in hand the diag-
nosis of Wolfram syndrome now seems clear for the
patient presented here, his late age of onset and the pro-
minence of his amnesia are quite atypical for this syn-
drome and made the diagnosis seem less likely.
Furthermore, the clinical presentation, mtDNA dele-
tions, and biochemical data were highly suggestive of a
mitochondrial disorder.
Given the multiple organ system dysfunction charac-
teristic of Wolfram syndrome, it was initially thought by
a number of clinicians to be a bona fide mitochondrial
disorder [13]. Further supporting this hypothesis was
the observation of mtDNA deletions in some patients
with Wolfram syndrome [14-16]. However, in 1998 two
groups identified WFS1, which encodes an 890 amino
acid trans-membrane protein localized to the endoplas-
mic reticulum, as the gene responsible for the majority
of Wolfram syndrome cases, thereby arguing against a
mitochondrial etiology [17,18]. Mechanistic studies of
WFS1 have revealed an important role in dampening
the ER stress response in pancreatic beta cells and neu-
rons, and loss of the gene has been shown to result in
an exaggerated stress response and accelerated cell
death [19]. However, given the shared clinical features
between Wolfram syndrome and many mitochondrial
disorders, as well as the presence of mtDNA deletions
in some patients, many unanswered questions remain
about the biology of WFS1 and its impact on mitochon-
drial function and mtDNA maintenance.
Mutations in residue 558 of WFS1, as identified in the
patient described here, have been previously reported.
Our patient’s p.R558C mutation was first reported as a
heterozygous variant in a cohort of psychiatric patients,
though it is unclear whether the variant contributed to
disease pathogenesis in that population [20]. Our
patient’s p.R558C mutation, as well as a p.R558H muta-
tion, have been reported in multiple patients with Wol-
fram syndrome [9,21,22]. Exome databases suggest that
the allele frequency of WFS1 c.1672C > T (p.R558C) is
quite rare; specifically, the variant is not found in the
1,000 Genomes Project [23] nor in over 2,500 publicly
available European and African American exomes [24].
Chaussenot et al. specifically discuss the phenotype of
a Wolfram case with the same p.R558C mutation identi-
fied in our patient in compound heterozygosity with a p.
F354del frameshift mutation [12]. Like our patient,
Chaussenot et al.’s case had significant cerebellar atro-
phy by MRI, neurogenic bladder symptoms, dementia,
DM, OA, as well as the absence of diabetes insipidus.
However, unlike our patient, the compound heterozy-
gote case had earlier onset of DM, OA, and neurologic
symptoms (at ages 9, 10, and 27 respectively), lacked
hearing impairment, and developed cerebellar ataxia and
nystagmus as part of her neurologic presentation. Of
note, the profound amnestic syndrome seen in our
patient was not reported for the compound heterozygote
case, and is atypical for Wolfram syndrome patients in
general. These cases demonstrate that phenotypic het-
erogeneity is present even among patients with similar
mutations, likely attributable to different genetic and
environmental backgrounds.
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tion in an autosomal dominant manner yielding symp-
toms such as optic atrophy and hearing impairment in a
heterozygous state [25,26]. The patient has one daughter
who struggled with Tourette syndrome and ADHD, but
the family history is otherwise unremarkable, with no
close family members suffering from symptoms asso-
ciated with Wolfram syndrome. No familial DNA was
available to determine the carrier status of his daughter.
It is unlikely that his daughter’s symptoms are related to
WFS1, and we suspect that the p.R558C variant likely
acts in a recessive manner.
One of the most striking aspects of the case presented
here is the profound thiamine deficiency, and its devastat-
ing impact on the patient’s memory. The symptom com-
plex of diabetes mellitus, deafness, and optic atrophy has
been found in association with defects in thiamine meta-
bolism previously in the context of thiamine-responsive
megaloblastic anemia syndrome, or Rogers syndrome
(OMIM # 249270) [27-29]. Rogers syndrome, a recessive
condition caused by mutations in the thiamine transporter
SLC19A2, is characterized by thiamine-responsive megalo-
blastic anemia, sensorineural deafness, and DM; its pheno-
typic similarity to Wolfram syndrome suggests the
possibility that disruption of thiamine metabolism may
contribute to the pathophysiology of Wolfram syndrome.
The coding exons of SLC19A2 were sequenced in our
patient and no rare mutations were detected, although the
presence of non-coding variants cannot be excluded.
Given that there was no dietary reason for our patient to
develop thiamine deficiency, his case suggests that WFS1
may impact thiamine transport or utilization. Further-
more, given that there are no therapies available for the
treatment of Wolfram syndrome, assessment of thiamine
sufficiency and possibly empiric thiamine supplementation
should be considered for these patients.
The patient presented here had a diagnostic journey
that is not unusual for disorders involving dysfunction
across multiple organ systems, in that several years
elapsed and numerous costly genetic tests were per-
formed without a molecular diagnosis. The application
of MitoExome sequencing in this case illustrates how
clinical application of next-generation sequencing tech-
nology can allow for rapid, simultaneous evaluation for
multiple genetic disorders with a single test thereby
accelerating the diagnostic process. Furthermore, this
case demonstrates how careful study of an individual
patient with a rare disorder can yield potentially new
insight into gene function and disease pathogenesis.
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